Field
This application relates generally to minimally-invasive devices, systems and methods of energy delivery to a targeted anatomical location of a subject, and more specifically, to catheter-based, intraluminal devices and systems configured to emit ultrasonic energy for the neuromodulation (e.g., ablation, necrosing, etc.) of nerve tissue.
Description of the Related Art
Catheter-based energy delivery systems can be used to access and treat portions of a subject's anatomy minimally-invasively. Such systems can be advanced through a subject's vasculature to reach a target anatomical site. The various embodiments disclosed herein provide improved devices, systems and methods related to energy delivery within a subject.
According to some embodiments, an intravascular, ultrasound-based ablation system includes a catheter comprising a guidewire lumen, at least one cable lumen and at least one fluid lumen, and a balloon or other expandable structure or member positioned at a distal end of the catheter, wherein an interior of the balloon is in fluid communication with the at least one fluid lumen of the catheter. In some embodiments, the balloon is configured to inflate when fluid (e.g., cooling fluid) is delivered into the interior through the at least one fluid lumen of the catheter. The system further comprises a tip extending distally from a distal end of the balloon, wherein the tip comprises an internal guidewire passage, and one or more ultrasound transducers positioned within the balloon. In some embodiments, the ultrasound transducer includes a cylindrical tube with inner and outer surfaces, each of the inner and outer surfaces comprising an electrode, wherein the ultrasound transducer defines an internal space adjacent the inner electrode surface, the internal space being in fluid communication with the interior cavity of the balloon so that, when in use, fluid entering the balloon passes along both the inner and outer surfaces to transfer heat away from the ultrasound transducer.
In some embodiments, at least one electrical cable (e.g., coaxial cable) is routed or otherwise positioned within the at least one cable lumen of the catheter, wherein the at least one electrical cable is electrically coupled to the electrodes along the inner and outer surfaces of the ultrasound transducer. The system further includes a backing member or post extending from the catheter to the tip and connecting the catheter with the tip. In some embodiments, the backing member is positioned within the internal space of the ultrasound transducer, wherein the backing member comprises a central opening that is generally aligned with the guidewire lumen of the catheter and the internal guidewire passage of the tip to permit the system to be delivered to a desired vascular position over a guidewire. In some embodiments, the backing member serves as a fluid barrier between fluid circulated within the balloon interior and the central opening.
According to some embodiments, the backing member comprises an electrically insulating material (e.g., polyimide, another polymeric material, etc.) along an interior surface of the central opening of the backing member so as to prevent electrical conduction between a guidewire and the backing member. In some embodiments, the guidewire lumen extends from a proximal end of the catheter to the balloon. In other embodiments, the guidewire lumen extends from a location between the proximal and distal ends of the catheter to the distal end of the catheter, such that the catheter comprises a rapid exchange design.
According to some embodiments, an intravascular, ultrasound-based ablation system comprises a catheter having at least one cable lumen and at least one fluid lumen, a balloon or other expandable structure positioned at a distal end of the catheter, an interior of the balloon being in fluid communication with the at least one fluid lumen of the catheter and an ultrasound transducer positioned within the balloon, wherein the ultrasound transducer comprises a cylindrical tube having a proximal end and a distal end and inner and outer surfaces. In some embodiments, each of the inner and outer surfaces comprises an electrode, wherein the proximal end of the cylindrical tube comprising a stepped portion, and wherein a portion of the outer diameter formed by the outer surface of the cylindrical tube is smaller than a portion of the outer diameter of the cylindrical tube located distal to the stepped portion. The system further comprises at least one electrical cable positioned within the at least one cable lumen of the catheter, the at least one electrical cable being configured to supply electrical power to the ultrasound transducer, wherein the at least one electrical cable comprises a first conductor and a second conductor.
In some embodiments, the system further comprises one or more a stand-off assemblies located within an interior and along or near the proximal end of the cylindrical tube of the ultrasound transducer. In one embodiment, the stand-off assembly is electrically conductive and in contact with, at least intermittently, the electrode along the inner surface of the cylindrical tube of the ultrasound transducer, wherein the first conductor is connected to an exterior of the cylindrical tube along the stepped portion, and wherein the second conductor is connected to the stand-off assembly so that the second conductor is electrically coupled to the electrode along the inner surface of the cylindrical tube. The system further comprise a ring surrounding the stepped portion of the cylindrical tube, the ring being sized and shaped to surround the portion of the outer diameter of the cylindrical tube located distal to the stepped portion, wherein the ring is electrically conductive so that the first connector is electrically coupled to the electrode along the outer surface of the cylindrical tube, and wherein the ring allows for more uniform electrical loading of the ultrasound transducer when the electrical transducer is energized.
According to some embodiments, the ring comprises conductive solder. In some embodiments, the ring comprises a conductive machined ring or other member or feature that couples around the stepped portion of the cylindrical tube. In some embodiments, the stepped portion extends approximately 5% to 25% of a length of the cylindrical tube. In one embodiment, the stepped portion comprises a portion of the cylindrical tube that is removed using grinding or other removal techniques. In some embodiments, an impedance of the at least one electrical cable substantially matches an impedance of the ultrasound transducer. In some embodiments, the impedance of the electrical cable and the ultrasound transducer is approximately 40 to 60 ohms (e.g., 50 ohms).
According to some embodiments, an intravascular, ultrasound-based ablation system comprises a catheter having a cable lumen extending from a proximal end to a distal end of the catheter, an ultrasound transducer positioned at or near a distal end of the catheter, wherein the ultrasound transducer comprises a cylindrical tube with inner and outer surfaces, wherein each of the inner and outer surface comprising an electrode. The system further comprises a backing member or post extending from the distal end of the catheter and positioned within an interior of the ultrasound transducer, wherein the backing member is configured to support the ultrasound transducer, and wherein the backing member is electrically coupled to the electrode along the inner surface of the cylindrical tube of the ultrasound transducer. In some embodiments, the system comprises an electrical cable positioned within the cable lumen of the catheter and extending from the proximal end to the distal end of the catheter, wherein a proximal end of the electrical cable is coupled to a generator configured to selectively provide electrical power to the ultrasound transducer through the electrical cable. In one embodiment, the electrical cable comprises a first electrical connector and a second electrical connector, wherein the first connector is electrically coupled to the electrode along the outer surface of the ultrasound transducer, and wherein the second connector is electrically coupled to the backing member and the electrode along the inner surface of the ultrasound transducer. In some embodiments, an impedance of the electrical cable is substantially equal to an impedance of the ultrasound transducer, thereby providing a more efficient power transfer from the generator to the ultrasound transducer when the ablation system is in use.
According to some embodiments, the electrical cable comprises a coaxial cable. In one embodiment, the backing member or post comprises at least one stand-off assembly that electrically couples the backing member to the electrode along the inner surface of the cylindrical tube of the ultrasound transducer. In some embodiments, the backing member or post is coupled to both the proximal and the distal ends of the transducer. In some embodiments, the impedance of the electrical cable and the ultrasound transducer is approximately 40 to 60 ohms (e.g., approximately 50 ohms). In some embodiments, the first connector of the electrical cable is electrically coupled to the electrode while not physically attached to the outer surface of the ultrasound transducer.
According to some embodiments, an intravascular, ultrasound-based ablation system includes a catheter comprising at least one fluid lumen, a balloon or other expandable member positioned at a distal end of the catheter, wherein an interior of the balloon is in fluid communication with the at least one fluid lumen of the catheter, and wherein the balloon is configured to inflate when fluid is delivered into the interior through the at least one lumen of the catheter. The system further comprises an ultrasound transducer positioned within the balloon, wherein the ultrasound transducer includes a cylindrical tube with inner and outer surfaces, wherein each of the inner and outer surface comprising an electrode. In some embodiments, the ultrasound transducer defines an internal space adjacent the inner electrode surface, wherein the internal space is in fluid communication with the interior cavity of the balloon so that, when in use, fluid entering the balloon passes along both the inner and outer surfaces to cool the ultrasound transducer. In some embodiments, the system additionally comprises a fluid transfer device configured to selectively deliver a cooling fluid within the balloon when the ultrasound transducer is activated in order to transfer heat away from the ultrasound transducer during use, wherein the fluid transfer device comprises a reservoir for storing a volume of cooling fluid and a movable member configured to move within an interior of the reservoir in order to transfer cooling fluid through the at least one fluid lumen of the catheter to the balloon, and wherein the reservoir is sized to store sufficient cooling fluid for an entire ablation procedure.
According to some embodiments, the movable member is coupled to a motor for selectively advancing the movable member relative to the reservoir. In one embodiment, the motor comprises a stepper motor or another type of motor. In some embodiments, the fluid transfer device comprises a syringe pump. In some embodiments, the catheter comprises a fluid delivery lumen and a fluid return lumen, wherein cooling fluid is delivered to the balloon from the fluid transfer device via the fluid delivery lumen, and wherein cooling fluid is withdrawn from the balloon via the fluid return lumen. In some embodiments, the fluid transfer lumen is in fluid communication with a first fluid transfer device, and wherein the fluid return lumen is in fluid communication with a second fluid transfer device, wherein both the first and the second fluid transfer devices are operated simultaneously to circulate cooling fluid through the balloon during an ablation procedure. In some embodiments, the fluid transfer device is configured to deliver cooling fluid through the at least one fluid lumen of the catheter and into the balloon at a flowrate of 30-50 ml/min (e.g., about 40 ml/min).
A method of intraluminally ablating or otherwise neuromodulating nerve tissue using an ultrasound-based ablation system includes advancing a catheter of the ablation system intraluminally to a target anatomical location of a subject, wherein the system comprises a balloon positioned at a distal end of the catheter, an interior of the balloon being in fluid communication with at least one fluid delivery lumen and at least one fluid return lumen of the catheter, wherein an ultrasound transducer is positioned within the interior of the balloon. The method further includes circulating cooling fluid through the interior of the balloon by transferring cooling fluid from a fluid transfer device through the at least one fluid lumen of the catheter and transferring cooling fluid away from the interior of the balloon through the at least one fluid return lumen and activating the ultrasound transducer positioned within the balloon to ablate nerve tissue adjacent to the target anatomical location of the subject. In some embodiments, cooling fluid is circulated adjacent the ultrasound transducer within the balloon when the ultrasound transducer is activated. In some embodiments, the fluid transfer device comprises a reservoir for storing a volume of cooling fluid and a movable member configured to move within an interior of the reservoir in order to transfer cooling fluid through the at least one fluid lumen of the catheter to the balloon, wherein the reservoir is sized to store sufficient cooling fluid for an entire ablation procedure.
According to some embodiments, the movable member (e.g., plunger) is coupled to a motor for selectively advancing the movable member relative to the reservoir. In one embodiment, the motor comprises a stepper motor or another type of motor or actuator. In some embodiments, the fluid transfer device comprises a syringe pump or another type of pump. In some embodiments, cooling fluid is circulated through the balloon at a flowrate of 30-50 ml/min (e.g., about 40 ml/min).
According to some embodiments, a coupling configured for use in an outlet of a fluid container (e.g., IV bag) includes a hub configured to abut against the outlet of the coupling, wherein the hub is configured to prevent over-insertion of the coupling into the fluid container. In some embodiments, a proximal end of the hub comprises a fitting configured for attachment to a fluid conduit. The coupling further comprises a spike portion extending distally from the hub, wherein a length of the spike is 0.5 inches to 3 inches. In some embodiments, the coupling comprises at least two fluid lumens (e.g., 2, 3, 4, 5, more than 5, etc.) that extend throughout an entire length of the coupling from the proximal end of the hub to a distal end of the spike, wherein the lumens place an interior of the fluid container in fluid communication with at least one fluid conduit secured to the hub. In some embodiments, the coupling permits at two different fluid sources to be placed in fluid communication with an interior of a fluid container comprising only a single outlet. In some embodiments, such a coupling or spike can be used on an IV bag or other fluid container that is placed in fluid communication with a syringe pump of a treatment system. Thus, the IV bag can be configured to store additional fluid that will be delivered through a delivery lumen into a balloon and/or can be configured to store excess fluid being returned from the balloon via a return lumen in the catheter. Thus, the coupling can be placed in fluid communication with the catheter and/or the syringe pump of the treatment system.
In some embodiments, the spike includes a taper along at least a portion of its length, so that a cross-sectional dimension of the spike is smaller along the distal end of the spike than a cross-sectional dimension of the spike along a proximal end of the spike. In some embodiments, the spike comprises a cone-shaped, with either a linear or non-linear (e.g., curved) profile. In some embodiments, the spike is configured for placement into an IV bag comprising only a single outlet or port. In some embodiments, the coupling comprises two fluid lumens.
In the various embodiments described herein, catheter-based systems and methods for treating targeted tissue of a subject are disclosed. The systems and methods are particularly useful in neuromodulation procedures (e.g., denervation). For example, as discussed in greater detail herein, the systems can be used to target select nerve tissue of the subject. Targeted nerve tissue can be heated by the application of ultrasonic energy thereto in order to neuromodulate (e.g., ablate, necrose, stimulate, etc.) the tissue. In other embodiments, the application of ultrasonic energy can be used to target other adjacent tissue of a subject, either in lieu of or in addition to nerve tissue. Accordingly, the systems and methods disclosed herein can be used to treat hypertension, other nerve-mediated diseases and/or any other ailment. The systems and methods disclosed herein can also be used in ablative procedures of non-nerve tissue (including, but not limited to, tumors, cardiac tissue, and other tissue types). Arrhythmias are treated according to one embodiment.
The catheter-based systems disclosed herein can be delivered intraluminally (e.g., intravascularly) to a target anatomical region of the subject, such as, for example, the renal artery, another targeted vessel or lumen, etc. Once properly positioned within the target vessel, the ultrasound transducer can be activated to selectively deliver acoustic energy radially outwardly from a distal end of the system and toward the targeted tissue. The transducer can be activated for a particular time period and at a particular energy level (e.g., power, frequency, etc.) in order to accomplish the desired effect on the targeted tissue. In embodiments where the targeted tissue is nerve tissue, the systems are configured to deliver ultrasonic energy through the adjacent wall of the vessel in which the system is positioned. For example, with respect to the renal artery, targeted nerve tissue is typically located about 0.5 mm to 8 mm (e.g., 1 mm to 6 mm) from the vessel wall. Accordingly, ultrasonic energy can be used to heat the nerve tissue in order to at least partially neuromodulate the nerve tissue. As used herein, neuromodulation shall be given its ordinary meaning and shall include, without limitation, complete or partial ablation, necrosis, stimulation and/or the like. In some embodiments, the acoustic energy is delivered radially outwardly from the ultrasound transducer, permitting the delivery of ultrasonic energy to target nerve tissue regardless of the radial orientation of such nerve tissue relative to a vessel (e.g., renal artery). Further, as discussed in greater detail herein, the various systems disclosed herein can be configured to deliver a cooling fluid to the anatomical region being treated in order to protect certain tissue of the subject (e.g., to prevent or reduce the likelihood of stenosis or other damage to the wall of the vessel through which energy is delivered during a procedure).
General System Components and Features
In some embodiments, the catheter 12 includes one or more lumens that can be used as fluid conduits, electrical cable passageways, guidewire lumen and/or the like. For example, as illustrated in
The catheter 12 can also include at least one fluid lumen 26 for transferring cooling fluid (e.g., water, saline, other liquids or gases, etc.) to and from the balloon or other expandable member 14 located at the distal end of the system. As discussed in greater detail herein, in some embodiments, the catheter comprises at least two fluid lumens 26, one for delivering cooling fluid to the balloon and the other for returning the cooling fluid from the balloon. However, the catheter 12 can include only a single fluid lumen or more than two fluid lumen (e.g., 3, 4, more than 4, etc.), as desired or required.
As illustrated in
Additional details regarding possible ultrasonic transducer designs and embodiments (e.g., both structurally and operationally) and/or catheter-based ultrasound delivery systems are provided in U.S. patent application Ser. No. 11/267,123, filed on Jul. 13, 2001 and published as U.S. Publ. No. 2002/0068885 on Jun. 6, 2002; U.S. patent application Ser. No. 09/905,227, filed Jul. 13, 2001 and issued as U.S. Pat. No. 6,635,054 on Oct. 21, 2003; U.S. patent application Ser. No. 09/904,620, filed on Jul. 13, 2001 and issued as U.S. Pat. No. 6,763,722 on Jul. 20, 2004; U.S. patent application Ser. No. 10/783,310, filed Feb. 20, 2004 and issued as U.S. Pat. No. 7,837,676 on Nov. 23, 2010; U.S. patent application Ser. No. 12/227,508, filed on Feb. 3, 2010 and published as U.S. Publ. No. 2010/0130892 on May 27, 2010; U.S. patent application Ser. No. 10/611,838, filed on Jun. 30, 2003 and published as U.S. Publ. No. 2004/0082859 on Apr. 29, 2004; and PCT Appl. No. PCT/US2011/025543, filed on Feb. 18, 2011 and published as PCT Publ. No. WO 2012/112165 on Aug. 23, 2012. The entireties of all the foregoing applications is hereby incorporated by reference herein and made a part of the present application.
With continued reference to
The system 100 can be delivered to the target anatomical location (e.g., a renal artery) via femoral, radial or other intravascular access. The system can be delivered through the vasculature or other lumen of the subject either with or without the assistance of a guidewire. Accordingly, as discussed in greater detail below, the catheter and other components of the system can include a guidewire lumen or other passages to permit delivery over a guidewire.
In some embodiments, the ultrasonic transducers are operated in a range of from 1 to 20 MHz (e.g., 1-5 MHz, 5-10 MHz, 10-15 MHz, 15-20 MHz, 8-10 MHz, other values or ranges within the foregoing, etc.). In one embodiment, for example, the ultrasound transducer of the system is configured to operate at a frequency of about 9 MHz. In other embodiments, however, the frequency at which a transducer is operated can be below 1 MHz or above 20 MHz. The power supplied to the ultrasound transducer can vary, as desired or required, and in some embodiments, is 5 to 80 Watts (e.g., 5 to 50, 5 to 10, 10 to 20, 20 to 30, to 40, 40 to 50, 50 to 60, 60 to 70, 70 to 80 Watts, etc.) at the transducer. As noted above, the period of time during which the ultrasound is activated for a particular treatment procedure can vary, and can also depend on one or more other factors, such as, for example, the power level at the transducer, the frequency of ultrasonic energy emitted, the size of the vessel or other tissue being treated, the age, weight and gender of the patient being treated and/or the like. However, in some embodiments, the ultrasonic transducer is activated for about 10 seconds to 5 minutes (e.g., 30 seconds to 5 minutes, 1 to 3 minutes, about 2 minutes, 10 seconds to 1 minute, 1 to 2 minutes, 2 to 3 minutes, 3 to 4 minutes, 4 to 5 minutes, etc.).
Referring now to
Guidewire-Enabled Catheter System
As noted above, the ultrasound treatment systems described herein can be configured to be delivered to a target anatomical location of a subject with or without the use of a guidewire.
With continued reference to
In order to permit liquid cooling along both the inner and outer electrodes 46, 48, the transducer can include one or more stand-off assemblies 50. As shown schematically in
With reference to
With further reference to
According to some embodiments, as illustrated in
The backing member 56 can advantageously serve as a fluid barrier between the cooling fluid circulated within the expandable member 14 and the central opening, lumen or passage 62 through which the guidewire is routed. In some embodiments, the backing member or post 56 can include one or more layers of an electrically insulating material or member 57 (e.g., polyimide) along an interior surface of the central opening 62 of the backing member 56 so as to prevent electrical conduction between the guidewire 58 and the backing member 56. Such an electrically insulating member 57 can also provide one or more other benefits to the system, such as, for example, reduced friction between the guidewire and the post. As illustrated in
Electrical Loading of Transducer
Accordingly, the acoustic energy profile of the transducer can be negatively affected by attaching anything to the outside and/or inside surfaces of the transducer tube (e.g., along the outer and/or inner electrodes of the transducer). For example, connecting an electrical conductor of the electrical cable that supplies current to the transducer can results in a diminished or undesirable acoustic energy profile. One embodiment for eliminating the need to attach any electrical conductors or other leads to the outer and inner electrodes of a transducer is illustrated in
In
With continued reference to
In one embodiment, the stepped portion 68 can be fabricated by machining and/or grinding away a proximal portion of the tube's outer diameter 66a. As noted above, such a step can include a uniform or constant outer diameter; however, in other embodiments, the stepped portion comprises a non-flat (e.g., rounded, curved, sloped, etc.) or irregular profile, as desired or required. In other embodiments, the stepped portion 68 can be fabricated by manufacturing the cylindrical tube 44 as a single piece of material with the step integrated into the tube during formation (e.g., by casting or molding the step into the original design). In yet another embodiment, the cylindrical tube 44 with the step can be created as two separate components (e.g., one with a larger diameter and one with the step diameter) which are bonded together (e.g., by welds, adhesives, rivets, screws, threaded couplings or features on the tube itself, press-fit connections, other mechanical or non-mechanical features, etc.).
In one embodiment, the electrical cable 28 that supplies current to the transducer comprises a coaxial cable having an inner conductor 28a and outer tubular conducting shield 28b. As shown in
With continued reference to
In other embodiments, one or more other components can be placed over the stepped portion 68 of the tube. For example, one or more layers of solder or other masses of at least partially electrically conductive can be deposited and secured to the outside of the stepped portion. Such layers or masses can include an outer diameter that matches the outer diameter 66a of the non-stepped portion 66 of the transducer. In some embodiments, an outer surface of the conductive electrical solder or other material or component placed along the outside of the stepped portion is reshaped or otherwise treated to achieve a substantially uniform overall outer diameter for the transducer (e.g., by mechanical grinding, etching, or polishing).
In some embodiments, the stepped portion 68 extends approximately 5% to 25% (e.g., 5% to 10%, 10% to 15%, 15% to 20%, 20% to 25%, etc.) of a length of the cylindrical tube 44. For example, the stepped portion 68 (and the corresponding ring, solder or other material or component placed around the stepped portion) can be approximately 1 mm in length, while the non-stepped portion 66 can be approximately 5 mm in length.
Alternatively, the cylindrical tube 44 can include a stepped portion 68 without an electrically conductive ring or other component 72. In such embodiments, the stepped portion 68 can form an inactive portion of the transducer 16 and the distal, non-stepped portion 66 can form the active portion of the transducer 16. One or more electrical connections (e.g., wires, other conductors, traces, etc.) can be placed along the inactive stepped portion and be routed to the outer electrode of the non-stepped portion 66 of the transducer.
Electrical Impedance Matching
As discussed herein, the ultrasonic transducer 16 can convert input electrical energy into ultrasonic energy that is delivered radially outwardly (e.g., toward target nerve tissue adjacent a vessel wall). In some embodiments, for ultrasonic transducers, the power factor, or conversion rate from electrical energy into generated acoustical energy, can be relatively low. Thus, a large portion of the electrical power delivered by the power supply may be lost as wasted heat. Accordingly, in one embodiment, to increase the efficiency of the ultrasound system, the electrical impedance of the electrical conductors (e.g., the one or more electrical cables 28 that electrically couple the transducer to the power supply) can be matched or substantially matched (e.g., within about 0-10%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.5-1%, 1-2%, 2-3%, 3-4%, 4-5%, 5-6%, 6-7%, 7-8%, 8-9%, 9-10%, etc.) to the electrical impedance of the ultrasound transducer 44. Thus, in some embodiments, by matching or substantially matching the impedance values of the cable and the transducer, the electrical load of the system can help reduce or minimize the electrical inefficiency of the system, while increasing or maximizing the amount of power transferred to the transducer.
Accordingly, in some embodiments, the ultrasound system 100 comprises only a single cable (e.g., coaxial cable) routed through a corresponding lumen of the catheter and electrically coupled to the transducer. The electrical cable can be selected to match or substantially match an impedance of the ultrasound transducer. For example, in some embodiments, the impedance of both the electrical cable and the ultrasound transducer is approximately 40 to 60 ohms (e.g., 50, 40-42, 42-44, 44-46, 46-48, 48-50, 50-52, 52-54, 54-56, 56-58, 58-60 ohms, etc.). In other embodiments, the impedance of the electrical cable and the ultrasound transducer can be less than 40 ohms or greater than 60 ohms, as desired or required.
Cooling Fluid Considerations
According to some embodiments, the cooling fluid that is circulated through the balloon at the distal end of the system can include, for example, saline, water or any other liquid or fluid. The cooling fluid can be room temperature or actively cooled (e.g., relative to room temperature, body temperature, etc.), as desired or required. In some embodiments, cooling fluid is circulated through the system in such a manner so that a the temperature along the interior wall of the vessel surrounding the transducer is maintained at a temperature of about 50-55° C. (e.g., 50° C., 51° C., 52° C., 53° C., 54° C., 55° C., etc.). In addition, in some embodiments, the temperature of the vessel wall is maintained within such a target range (e.g., 50-55° C.), while the temperature of tissue approximately 0.5 mm to 8 mm (e.g., 1 mm to 6 mm, where, in some embodiments, target tissue is located) is heated to about 60-80° C. (e.g., 60-70° C., 70-80° C., 65-75° C., etc.) when the transducer is activated. The higher temperature at a particular distance away from the vessel wall can be due, at least in part, on the less effective cooling by the cooling fluid at those distances away from the balloon. In some embodiments, raising the temperature of nerve and/or other nerve tissue to about 60-80° C. can help perform the desired neuromodulation (e.g., ablation, necrosing, etc.) to such tissue. A treatment protocol that accomplishes the desired heating of the targeted tissue (e.g. nerves) while maintaining adjacent vessel tissue to safe levels (e.g., to reduce the likelihood of stenosis or other damage to such tissue) can be based, either completely or in part, on empirical or experimental data.
Certain vessels (e.g., renal arteries) in which the system can be placed can have a relatively small catheter diameter. As a result, the diameter of the fluid lumens 26a, 26b located within the catheter may also need to be reduced. As the diameter of the fluid lumens 26 are decreased, the pressure required to move the cooling fluid increases (e.g., due to an increase in back pressure and head losses through the fluid lumens). As a result, increased cooling fluid pressure can be required by one or more of the pumps or other fluid transfer devices in fluid communication with the system. However, if the system fluid pressure is increased to a high enough value, the increased pressure of the balloon can create one or more safety concerns. For example, the balloon itself may be susceptible to rupture or other damage. Further, the pressure created within the balloon can cause the balloon to expand to a degree that poses a risk of harm to the adjacent tissue of the subject (e.g., the artery or other vessel of the subject may rupture or otherwise be damaged). Accordingly, in some embodiments, it is desirable to regulate and limit the pressure within the balloon. For example, in some embodiments, the internal pressure of the balloon 14 is maintained at about 1.5-2 ATM (e.g., for a 6 FR catheter).
As illustrated in
In one embodiment, the pumps P or other fluid transfer devices that are placed in fluid communication with the fluid lumens 26a, 26b comprise positive displacement pump, such as a peristaltic pump. However, in some circumstances, when the back-pressures associated with delivering the cooling fluid to the balloon is above a particular threshold, peristaltic pumps or similar positive displacement pumps are unable to deliver the necessary flowrate of cooling fluid to the balloon.
Accordingly, in some embodiments, one or more pumps P of the systems can comprise a syringe pump. A syringe pump can include a reservoir for storing a volume of cooling fluid and a movable member configured to move (e.g., slide) within an interior of the reservoir. The movement of the movable member within the corresponding reservoir exerts the necessary backpressure on the fluid (e.g., cooling fluid) stored within the reservoir and transfers the fluid through the fluid delivery lumen 26a of the catheter and into the balloon. In some embodiments, the use of such syringe pumps can provide sufficient force to achieve the required backpressure at a desired flowrate of cooling fluid. The movable members of syringe or other such pumps can be selectively moved by one or more stepper motors or other mechanical devices. In such embodiments, the stepper motor can prevent and/or minimize deflection of the movable member caused by the corresponding torques, moments and forces.
According to some embodiments, the reservoir of the syringe or other pump P in fluid communication with the fluid lumen 26a and the balloon 14 is sized and otherwise configured to store a sufficient volume of cooling fluid for an entire treatment procedure. In some embodiments, the volume of the reservoir is approximately 50 ml to 1,000 ml (e.g., 50-100, 100-200, 200-300, 300-400, 400-500, 500-600, 600-700, 700-800, 800-900, 900-1,000 ml, capacities between the foregoing, etc.).
In one embodiment, the fluid lumens 26 can be operated simultaneously to circulate cooling fluid through the expandable members 14 during an ablation procedure. In one embodiment, the flowrate of cooling fluid through the lumens 26 can be between 30-50 ml/min (e.g., 30-40 ml/min, 40-50 ml/min, 35-45 ml/min, 40 ml/min).
IV Bag Connector
IV bags used for the storage of cooling fluid in connection with the various systems disclosed herein can have two outlet ports (e.g., for mating to the two fluid lumens 26 of the catheter). In other embodiments, however, the IV bag 200 is constructed with only a single inlet/outlet port 210, as depicted in
In some embodiments, the dual lumen spike or coupling 74 can comprise two or more lumens or passages 76, 78 that are separated from one another. Such separate passage 76, 78 can be connected to different fluid conduit or sources, as desired or required. As shown, the spike 74 can include a proximal hub 82 that is shaped, sized and otherwise configured to abut against an end of bag's port 210 (or other inlet or outlet). A proximal conduit 84 can be inserted within or otherwise placed in fluid communication with one or more fluid sources (e.g., lumen of a catheter as disclosed herein, a pump, etc.). In some embodiments, the spike can include a minimum penetration depth 80 into the IV bag to ensure adequate flow (e.g., supply and return) into and out of the bag. Such a minimum penetration depth can help prevent or reduce the likelihood of short-circuiting of fluids entering and exiting the bag 200. In some embodiments, the inner diameters of the internal lumens or passages 76, 78 of the spike or coupling 74 are approximately 0.05 to 0.125 inches (e.g., 0.05-0.06, 0.06-0.07, 0.07-0.08, 0.08-0.09, 0.09-0.1, 0.1-0.11, 0.11-0.125, diameter between the foregoing, etc.) and the minimum penetration distance 80 is about 1.5 inches (e.g., 0.75, 1.0, 1.25, 1.5 inches, distances between the foregoing, less than 0.75 inches, more than 1.5 inches, 1.5-2.0 inches, 2.0-3.0 inches, more than about 3 inches, etc.).
In some embodiments, such a coupling or spike 74 can be used on an IV bag or other fluid container that is placed in fluid communication with a syringe pump of a treatment system. Thus, the IV bag can be configured to store additional fluid that will be delivered through a delivery lumen into a balloon and/or can be configured to store excess fluid being returned from the balloon via a return lumen in the catheter. Thus, the coupling 74 can be placed in fluid communication with the catheter and/or the syringe pump of the treatment system.
Vessel Diameter Detection
In some embodiments, prior to inflation of a balloon or other expandable member 14, the ultrasonic transducer 16 can be activated to measure the vessel's diameter. This can be accomplished by sending out a single (or a distinct number of) ultrasonic waves and recording the time period required for the signals to return (e.g., bounce back) to the transducer surface. Thus, in some embodiments, a control system of the system can be configured to both emit acoustic energy and detect it (e.g., at or along the outside of the transducer). By detecting the diameter of the vessel (e.g., renal artery) at a desired treatment location, the clinician can make any necessary adjustments to the procedure (e.g., what size balloon to use, how much energy should be delivered to the subject and for what time period, etc.).
Miscellaneous Concepts
In any of the embodiments disclosed herein, the system can comprise an ultrasound transducer having a variety of shapes. The transducer can be cylindrical or non-cylindrical, as desired or required. For example, in some embodiments, the transducer comprises, at least in part, an hourglass shape, a barbell shape, a convex shape or surface, a concave shape or surface and cone shape, an irregular shape and/or the like.
In some embodiments, a system can comprise an array of transducers (e.g., an array comprising 2, 3, 4, 5, 6, 7, 8, 9, 10, 10-15, more than 15 transducers, etc.). In embodiments comprising 2 or more transducers (e.g., an array of transducers), one or more of the transducers can be configured to emit more or less ultrasonic energy than one or more other transducers. In some embodiments, the amount of acoustic energy that is emitted by the plurality of transducers varies (e.g., linearly, non-linearly, randomly, etc.) along a longitudinal axis of the system. In some embodiments, one or some ultrasound transducer of a system emit (or are configured to emit) greater acoustic energy in one or more directions in relation to one or more other directions.
In any of the embodiments disclosed herein, an ultrasound transducer can include differing wall thickness (e.g., along its longitudinal axis). In embodiments comprising two or more transducers, the wall thickness of one transducer is greater or less than the wall thickness of another transducer. In some embodiments, one or more transducers of a system can be independently controllable (e.g., such that power and/or frequency to one transducer can be different than power and/or frequency to another transducer, etc.). In some embodiments, two or more transducers of a system are controlled together or in unison. In one embodiment, a transducer can include an eccentric or non-uniform backing lumen or opening.
In any of the embodiments disclosed herein, the transducer comprises a varying wall thickness along at least a portion of its circumferential extent. Accordingly, rotating the transducer can alter the acoustic energy pattern emitted by the transducer and/or alter one or more other aspects of energy emission (e.g., frequency, efficiency, etc.) during use. In some embodiments, one or more regions, surfaces and/or other portions of a transducer can be at least partially masked, covered, obstructed, etc. in order to alter the acoustic energy profile of the transducer during use. For example, at least a portion of the transducer can be masked or otherwise covered by selective plating and/or etching of the electrodes along the transducer, covering a portion of the transducer, using one or more features of the balloon, etc.).
In some embodiments, ultrasonic energy is directed directly within the tissue of the targeted nerve tissue (e.g., sympathetic nerves). In any of the embodiments disclosed herein, a balloon and/or other expandable structure or member can be used to at least partially expand the area or volume of tissue being treated (e.g., the renal artery, other body lumen or vessel, etc. can be radially expanded). In some embodiments, an ablation system includes a balloon (e.g., positioned at least partially around one or more traducers), but no fluid is configured to be circulated through the balloon during use. For example, in one embodiment, the balloon can be inflated with one or more gases, liquids and/or fluids (e.g., in order to expand the balloon, so that balloon contacts the adjacent wall of the targeted vessel, so that the one or more transducers of the system are radially centered or generally radially centered within the vessel, etc.), but no fluids are circulated through the balloon. Thus, the balloon can be configured to maintain an inflated or expanded state without the continuous or intermittent delivery of fluid therethrough.
In some embodiments, a catheter of the system comprises a chip (e.g., a smart catheter) and/or one or more related components or features (e.g., an identification device or reader, a transducer, etc.). Accordingly, the generator can detect which catheter is being used. Further, the system can monitor one or more aspects of a therapy or procedure using one or more metrics that are detected, such as, for example, pressure, temperature, flowrate, vessel diameter, thermal profile, presence and/or degree of spasm of a vessel, degree of narrowing of a vessel and/or the like. Such information can be used in a control scheme to regulate one or more aspect of the generator and/or other components or devices of the system (e.g., to modulate power, frequency, duration of procedure, automatic shutoff, billing, patient records or other recordkeeping, memorization of a procedure for other reasons, etc.).
The features and attributes of the specific embodiments disclosed herein may be combined in different ways to form additional embodiments, all of which fall within the scope of the present disclosure. Although the concepts presented herein have been disclosed in the context of certain embodiments and examples, the present application extends beyond the specifically disclosed embodiments to other alternative embodiments and/or uses of the concepts disclosed herein and obvious modifications and equivalents thereof. The disclosure herein of any particular feature, aspect, method, property, characteristic, quality, attribute, element, or the like in connection with an embodiment can be used in all other embodiments set forth herein. The ranges disclosed herein also encompass any and all overlap, sub-ranges, and combinations thereof. Language such as “up to,” “at least,” “greater than,” “less than,” “between,” and the like includes the number recited. Numbers preceded by a term such as “about” or “approximately” include the recited numbers. For example, “about 10 mm” includes “10 mm.” For all of the embodiments described herein the steps of the methods need not be performed sequentially. Thus, it is intended that the scope of the concepts disclosed herein should not be limited by the particular disclosed embodiments described above.
This application claims the priority benefit under 35 U.S.C. § 119(e) of U.S. Provisional Application No. 61/784,790, filed Mar. 14, 2013, the entirety of which is hereby incorporated by reference herein.
Number | Name | Date | Kind |
---|---|---|---|
3938502 | Bom | Feb 1976 | A |
4802490 | Johnston | Feb 1989 | A |
4841977 | Griffith | Jun 1989 | A |
5295992 | Cameron | Mar 1994 | A |
5295995 | Kleiman | Mar 1994 | A |
5308356 | Blackshear et al. | May 1994 | A |
5324255 | Passafaro et al. | Jun 1994 | A |
5327885 | Griffith | Jul 1994 | A |
5354200 | Klein et al. | Oct 1994 | A |
5354220 | Ganguly | Oct 1994 | A |
5400267 | Denen et al. | Mar 1995 | A |
5423220 | Finsterwald et al. | Jun 1995 | A |
5456259 | Barlow et al. | Oct 1995 | A |
5524491 | Cavalloni | Jun 1996 | A |
5620479 | Diederich | Apr 1997 | A |
5630837 | Crowley | May 1997 | A |
5713849 | Bosma et al. | Feb 1998 | A |
5722397 | Eppstein | Mar 1998 | A |
5769812 | Stevens et al. | Jun 1998 | A |
5775338 | Hastings | Jul 1998 | A |
5803083 | Buck et al. | Sep 1998 | A |
5938645 | Gordon | Aug 1999 | A |
6097985 | Kasevich et al. | Aug 2000 | A |
6102863 | Pflugrath et al. | Aug 2000 | A |
6117101 | Diederich et al. | Sep 2000 | A |
6128522 | Acker et al. | Oct 2000 | A |
6149596 | Bancroft | Nov 2000 | A |
6190377 | Kuzdrall | Feb 2001 | B1 |
6216704 | Ingle et al. | Apr 2001 | B1 |
6277077 | Brisken et al. | Aug 2001 | B1 |
6299583 | Eggers et al. | Oct 2001 | B1 |
6355030 | Aldrich et al. | Mar 2002 | B1 |
6475146 | Frelburger et al. | Nov 2002 | B1 |
6492762 | Pant et al. | Dec 2002 | B1 |
6517534 | McGovern et al. | Feb 2003 | B1 |
6599256 | Acker et al. | Jul 2003 | B1 |
6599288 | Maguire et al. | Jul 2003 | B2 |
6607502 | Maguire | Aug 2003 | B1 |
6635054 | Fjield et al. | Oct 2003 | B2 |
6645202 | Pless et al. | Nov 2003 | B1 |
6669638 | Miller et al. | Dec 2003 | B1 |
6712767 | Hossack et al. | Mar 2004 | B2 |
6740040 | Mandrusov et al. | May 2004 | B1 |
6763722 | Fjield et al. | Jul 2004 | B2 |
6793635 | Ryan et al. | Sep 2004 | B2 |
6913581 | Corl et al. | Jul 2005 | B2 |
6953469 | Ryan | Oct 2005 | B2 |
6978174 | Gelfand et al. | Dec 2005 | B2 |
7162303 | Levin et al. | Jan 2007 | B2 |
7285116 | De La Rama et al. | Oct 2007 | B2 |
7291413 | Allen et al. | Nov 2007 | B2 |
7297413 | Mitsumori | Nov 2007 | B2 |
7347852 | Hobbs et al. | Mar 2008 | B2 |
7473224 | Makin | Jan 2009 | B2 |
7540846 | Harhen et al. | Jun 2009 | B2 |
7573182 | Savage | Aug 2009 | B2 |
7591996 | Hwang et al. | Sep 2009 | B2 |
7617005 | Demarais et al. | Nov 2009 | B2 |
7620451 | Demarais et al. | Nov 2009 | B2 |
7625371 | Morris et al. | Dec 2009 | B2 |
7647115 | Levin et al. | Jan 2010 | B2 |
7653438 | Deem et al. | Jan 2010 | B2 |
7678104 | Keidar | Mar 2010 | B2 |
7717948 | Demarais et al. | May 2010 | B2 |
7756583 | Demarais et al. | Jul 2010 | B2 |
7837676 | Sinelnikov et al. | Nov 2010 | B2 |
7846317 | Meltzer et al. | Dec 2010 | B2 |
7873417 | Demarais et al. | Jan 2011 | B2 |
7937143 | Demarais et al. | May 2011 | B2 |
8131371 | Demarals et al. | Mar 2012 | B2 |
8233221 | Suijver et al. | Jul 2012 | B2 |
8251986 | Chornenky et al. | Aug 2012 | B2 |
8287472 | Ostrovsky et al. | Oct 2012 | B2 |
8475442 | Hall et al. | Jul 2013 | B2 |
8485993 | Orszulak et al. | Jul 2013 | B2 |
8504147 | Deem et al. | Aug 2013 | B2 |
D697036 | Kay et al. | Jan 2014 | S |
8715209 | Gertner | May 2014 | B2 |
8734438 | Behnke | May 2014 | B2 |
D708810 | Lewis, Jr. | Jul 2014 | S |
8808345 | Clark et al. | Aug 2014 | B2 |
D712352 | George et al. | Sep 2014 | S |
D712353 | George et al. | Sep 2014 | S |
D712833 | George et al. | Sep 2014 | S |
8974445 | Warnking et al. | Mar 2015 | B2 |
9675413 | Deem et al. | Jun 2017 | B2 |
9700372 | Schaer | Jul 2017 | B2 |
9707034 | Schaer | Jul 2017 | B2 |
9943666 | Warnking | Apr 2018 | B2 |
9981108 | Warnking | May 2018 | B2 |
10039901 | Warnking | Aug 2018 | B2 |
20010007940 | Tu et al. | Jul 2001 | A1 |
20020002334 | Okuno et al. | Jan 2002 | A1 |
20020002371 | Acker et al. | Jan 2002 | A1 |
20020062123 | McClurken et al. | May 2002 | A1 |
20020065512 | Fjield et al. | May 2002 | A1 |
20020087156 | Maguire et al. | Jul 2002 | A1 |
20020150693 | Kobayashi et al. | Oct 2002 | A1 |
20020151889 | Swanson et al. | Oct 2002 | A1 |
20020156469 | Yon et al. | Oct 2002 | A1 |
20020165535 | Lesh et al. | Nov 2002 | A1 |
20020193781 | Loeb | Dec 2002 | A1 |
20030060813 | Loeb et al. | Mar 2003 | A1 |
20030125726 | Maguire | Jul 2003 | A1 |
20030138571 | Kunishi et al. | Jul 2003 | A1 |
20030181963 | Pellegrino et al. | Sep 2003 | A1 |
20030204138 | Choi | Oct 2003 | A1 |
20030216721 | Diederich et al. | Nov 2003 | A1 |
20030216792 | Levin et al. | Nov 2003 | A1 |
20030216794 | Becker et al. | Nov 2003 | A1 |
20030225331 | Diederich et al. | Dec 2003 | A1 |
20030233099 | Danaek et al. | Dec 2003 | A1 |
20040044286 | Hossack et al. | Mar 2004 | A1 |
20040082859 | Schaer | Apr 2004 | A1 |
20040167415 | Gelfand et al. | Aug 2004 | A1 |
20040230116 | Cowan et al. | Nov 2004 | A1 |
20040253450 | Seita et al. | Dec 2004 | A1 |
20050009218 | Kunihiro | Jan 2005 | A1 |
20050035901 | Lyon | Feb 2005 | A1 |
20050215990 | Govari | Sep 2005 | A1 |
20050234523 | Levin et al. | Oct 2005 | A1 |
20050256518 | Rama et al. | Nov 2005 | A1 |
20050288730 | Deem et al. | Dec 2005 | A1 |
20060041277 | Deem et al. | Feb 2006 | A1 |
20060058711 | Harhen | Mar 2006 | A1 |
20060064081 | Rosinko | Mar 2006 | A1 |
20060088705 | Mitsumori | Apr 2006 | A1 |
20060100514 | Lopath | May 2006 | A1 |
20060121200 | Halpert et al. | Jun 2006 | A1 |
20060154072 | Schlossman et al. | Jul 2006 | A1 |
20060155269 | Warnking | Jul 2006 | A1 |
20060184072 | Manna | Aug 2006 | A1 |
20060212076 | Demarais et al. | Sep 2006 | A1 |
20060212078 | Demarais et al. | Sep 2006 | A1 |
20060229594 | Francischelli et al. | Oct 2006 | A1 |
20060241523 | Sinelnikov et al. | Oct 2006 | A1 |
20060265014 | Demarais et al. | Nov 2006 | A1 |
20060265015 | Demarais et al. | Nov 2006 | A1 |
20060270976 | Savage et al. | Nov 2006 | A1 |
20060276852 | Demarais et al. | Dec 2006 | A1 |
20070124458 | Kumar | May 2007 | A1 |
20070129720 | Demarais et al. | Jun 2007 | A1 |
20070129760 | Demarais et al. | Jun 2007 | A1 |
20070135875 | Demarais et al. | Jun 2007 | A1 |
20070173899 | Levin et al. | Jul 2007 | A1 |
20070175359 | Hwang | Aug 2007 | A1 |
20070203547 | Costello et al. | Aug 2007 | A1 |
20070203549 | Demarais et al. | Aug 2007 | A1 |
20070249046 | Shields, Jr. | Oct 2007 | A1 |
20070255267 | Diederich et al. | Nov 2007 | A1 |
20070255342 | Laufer | Nov 2007 | A1 |
20070265609 | Thapliyal et al. | Nov 2007 | A1 |
20070265610 | Thapliyal et al. | Nov 2007 | A1 |
20070265687 | Deem et al. | Nov 2007 | A1 |
20070282407 | Demarais et al. | Dec 2007 | A1 |
20070293762 | Sawada et al. | Dec 2007 | A1 |
20080052186 | Walker et al. | Feb 2008 | A1 |
20080151001 | Sudo et al. | Jun 2008 | A1 |
20080252172 | Yetter et al. | Oct 2008 | A1 |
20080255449 | Warnking et al. | Oct 2008 | A1 |
20080255478 | Burdette | Oct 2008 | A1 |
20080255642 | Zarins et al. | Oct 2008 | A1 |
20090024195 | Rezai et al. | Jan 2009 | A1 |
20090036948 | Levin et al. | Feb 2009 | A1 |
20090062873 | Wu et al. | Mar 2009 | A1 |
20090076409 | Wu et al. | Mar 2009 | A1 |
20090118125 | Kobayashi et al. | May 2009 | A1 |
20090118725 | Auth et al. | May 2009 | A1 |
20090124964 | Leach et al. | May 2009 | A1 |
20090149753 | Govari et al. | Jun 2009 | A1 |
20090171202 | Kirkpatrick et al. | Jul 2009 | A1 |
20090189485 | Iyoki | Jul 2009 | A1 |
20090204006 | Wakabayashi et al. | Aug 2009 | A1 |
20090221939 | Demarais et al. | Sep 2009 | A1 |
20090228003 | Sinelnikov | Sep 2009 | A1 |
20090248011 | Hlavka et al. | Oct 2009 | A1 |
20090299360 | Ormsby | Dec 2009 | A1 |
20090312673 | Thapliyal et al. | Dec 2009 | A1 |
20090312693 | Thapliyal et al. | Dec 2009 | A1 |
20090312755 | Thapliyal et al. | Dec 2009 | A1 |
20100016762 | Thapliyal et al. | Jan 2010 | A1 |
20100033940 | Yamaguchi et al. | Feb 2010 | A1 |
20100049099 | Thapliyal et al. | Feb 2010 | A1 |
20100113928 | Thapliyal et al. | May 2010 | A1 |
20100113985 | Thapliyal et al. | May 2010 | A1 |
20100114094 | Thapliyal et al. | May 2010 | A1 |
20100125198 | Thapliyal et al. | May 2010 | A1 |
20100130892 | Warnking | May 2010 | A1 |
20100137860 | Demarais et al. | Jun 2010 | A1 |
20100137952 | Demarais et al. | Jun 2010 | A1 |
20100152582 | Thapliyal et al. | Jun 2010 | A1 |
20100168731 | Wu et al. | Jul 2010 | A1 |
20100168737 | Grunewald | Jul 2010 | A1 |
20100168739 | Wu et al. | Jul 2010 | A1 |
20100174282 | Demarais et al. | Jul 2010 | A1 |
20100179424 | Warnking et al. | Jul 2010 | A1 |
20100189974 | Ochi et al. | Jul 2010 | A1 |
20100191112 | Demarais et al. | Jul 2010 | A1 |
20100198065 | Thapliyal et al. | Aug 2010 | A1 |
20100249859 | Dilorenzo | Sep 2010 | A1 |
20100291722 | Kim | Nov 2010 | A1 |
20110004184 | Proksch et al. | Jan 2011 | A1 |
20110060324 | Wu et al. | Mar 2011 | A1 |
20110087096 | Behar | Apr 2011 | A1 |
20110087097 | Behar | Apr 2011 | A1 |
20110104060 | Seward | May 2011 | A1 |
20110112400 | Emery et al. | May 2011 | A1 |
20110118598 | Gertner | May 2011 | A1 |
20110137298 | Nguyen et al. | Jun 2011 | A1 |
20110172527 | Gertner | Jul 2011 | A1 |
20110178516 | Orszulak et al. | Jul 2011 | A1 |
20110200171 | Beetel et al. | Aug 2011 | A1 |
20110208096 | Demarais et al. | Aug 2011 | A1 |
20110257523 | Hastings et al. | Oct 2011 | A1 |
20110257562 | Schaer | Oct 2011 | A1 |
20110257563 | Thapliyal et al. | Oct 2011 | A1 |
20110257564 | Demarais et al. | Oct 2011 | A1 |
20110301662 | Bar-Yoseph et al. | Dec 2011 | A1 |
20110319765 | Gertner et al. | Dec 2011 | A1 |
20120004656 | Jackson et al. | Jan 2012 | A1 |
20120065493 | Gertner | Mar 2012 | A1 |
20120065554 | Pikus | Mar 2012 | A1 |
20120078278 | Bales et al. | Mar 2012 | A1 |
20120095461 | Herscher et al. | Apr 2012 | A1 |
20120123243 | Hastings | May 2012 | A1 |
20120123303 | Sogard et al. | May 2012 | A1 |
20120143097 | Pike, Jr. | Jun 2012 | A1 |
20120165667 | Altmann et al. | Jun 2012 | A1 |
20120172723 | Gertner | Jul 2012 | A1 |
20120215106 | Sverdlik et al. | Aug 2012 | A1 |
20120232436 | Warnking | Sep 2012 | A1 |
20120238918 | Gertner | Sep 2012 | A1 |
20120238919 | Gertner | Sep 2012 | A1 |
20120265198 | Crow et al. | Oct 2012 | A1 |
20120316439 | Behar | Dec 2012 | A1 |
20130012844 | Demarais et al. | Jan 2013 | A1 |
20130072928 | Schaer | Mar 2013 | A1 |
20130090650 | Jenson et al. | Apr 2013 | A1 |
20130103064 | Arenson et al. | Apr 2013 | A1 |
20130110012 | Gertner | May 2013 | A1 |
20130131668 | Schaer | May 2013 | A1 |
20130138018 | Gertner | May 2013 | A1 |
20130158441 | Demarais et al. | Jun 2013 | A1 |
20130158442 | Demarais et al. | Jun 2013 | A1 |
20130165822 | Demarais et al. | Jun 2013 | A1 |
20130165924 | Mathur et al. | Jun 2013 | A1 |
20130197555 | Schaer | Aug 2013 | A1 |
20130204167 | Sverdlik et al. | Aug 2013 | A1 |
20130211396 | Sverdlik et al. | Aug 2013 | A1 |
20130211437 | Sverdlik et al. | Aug 2013 | A1 |
20130218054 | Sverdlik et al. | Aug 2013 | A1 |
20130274658 | Steinke et al. | Oct 2013 | A1 |
20130282084 | Mathur et al. | Oct 2013 | A1 |
20130304047 | Grunewald et al. | Nov 2013 | A1 |
20130331739 | Gertner | Dec 2013 | A1 |
20140012133 | Sverdlik et al. | Jan 2014 | A1 |
20140018794 | Anderson et al. | Jan 2014 | A1 |
20140025069 | Willard et al. | Jan 2014 | A1 |
20140031727 | Warnking | Jan 2014 | A1 |
20140039477 | Sverdlik et al. | Feb 2014 | A1 |
20140046313 | Pederson et al. | Feb 2014 | A1 |
20140067029 | Schauer et al. | Mar 2014 | A1 |
20140074083 | Horn et al. | Mar 2014 | A1 |
20140107639 | Zhang et al. | Apr 2014 | A1 |
20140163540 | Iyer et al. | Jun 2014 | A1 |
20140180196 | Stone et al. | Jun 2014 | A1 |
20140180197 | Sverdlik et al. | Jun 2014 | A1 |
20140194785 | Gertner | Jul 2014 | A1 |
20140200489 | Behar et al. | Jul 2014 | A1 |
20140214018 | Behar et al. | Jul 2014 | A1 |
20140249524 | Kocur | Sep 2014 | A1 |
20140272110 | Taylor et al. | Sep 2014 | A1 |
20140275924 | Min et al. | Sep 2014 | A1 |
20140276742 | Nabutovsky et al. | Sep 2014 | A1 |
20140276752 | Wang et al. | Sep 2014 | A1 |
20140276755 | Cao et al. | Sep 2014 | A1 |
20140276789 | Dandler et al. | Sep 2014 | A1 |
20140277033 | Taylor et al. | Sep 2014 | A1 |
20150223877 | Behar et al. | Aug 2015 | A1 |
20150290427 | Warnking | Oct 2015 | A1 |
20150335919 | Behar et al. | Nov 2015 | A1 |
20160016016 | Taylor et al. | Jan 2016 | A1 |
Number | Date | Country |
---|---|---|
1441651 | Sep 2003 | CN |
1763245.5 | Apr 2006 | CN |
20 2005 022 060 | Nov 2012 | DE |
0 623 360 | Nov 1994 | EP |
0 659 387 | Jun 1995 | EP |
0 767 630 | Apr 1997 | EP |
0 774 276 | May 1997 | EP |
0 838 980 | Apr 1998 | EP |
1 042 990 | Oct 2000 | EP |
1 100 375 | May 2001 | EP |
1 384 445 | Jan 2004 | EP |
1 598 024 | Nov 2005 | EP |
1 647 305 | Apr 2006 | EP |
2 218 479 | Aug 2010 | EP |
2 359 764 | Aug 2011 | EP |
2 457 614 | May 2012 | EP |
2 460 486 | Jun 2012 | EP |
2 495 012 | Sep 2012 | EP |
2 521 593 | Nov 2012 | EP |
2 561 903 | Feb 2013 | EP |
2 561 905 | Feb 2013 | EP |
2 626 022 | Aug 2013 | EP |
2 632 373 | Sep 2013 | EP |
2 662 041 | Nov 2013 | EP |
2 662 043 | Nov 2013 | EP |
2 037 166 | Jul 1980 | GB |
05-068684 | Mar 1993 | JP |
07-178173 | Jul 1995 | JP |
40-826437 | Oct 1996 | JP |
10-127678 | May 1998 | JP |
H-10-507229 | Jul 1998 | JP |
11-218100 | Aug 1999 | JP |
2000-054153 | Feb 2000 | JP |
2001-111126 | Apr 2001 | JP |
2002-078809 | Mar 2002 | JP |
2003-533265 | Nov 2003 | JP |
2004-503324 | Feb 2004 | JP |
2004-130096 | Apr 2004 | JP |
2005-526579 | Sep 2005 | JP |
2005-270662 | Oct 2005 | JP |
2006-161116 | Jun 2006 | JP |
2008-513056 | May 2008 | JP |
2008-515544 | May 2008 | JP |
2008-214669 | Sep 2008 | JP |
2010-503466 | Feb 2010 | JP |
2010-221038 | Oct 2010 | JP |
2011-219828 | Nov 2011 | JP |
WO-9000420 | Jan 1990 | WO |
WO-9207622 | May 1992 | WO |
WO-9220291 | Nov 1992 | WO |
WO-9405365 | Mar 1994 | WO |
WO-9411057 | May 1994 | WO |
WO-9519143 | Jul 1995 | WO |
WO-9525472 | Sep 1995 | WO |
WO-9600039 | Jan 1996 | WO |
WO-9713463 | Apr 1997 | WO |
WO-9736548 | Oct 1997 | WO |
WO-9841178 | Sep 1998 | WO |
WO-9842403 | Oct 1998 | WO |
WO-9849957 | Nov 1998 | WO |
WO-9852465 | Nov 1998 | WO |
WO-9902096 | Jan 1999 | WO |
WO-9935987 | Jul 1999 | WO |
WO-9944519 | Sep 1999 | WO |
WO-9944523 | Sep 1999 | WO |
WO-9952423 | Oct 1999 | WO |
WO-9956812 | Nov 1999 | WO |
WO-0016850 | Mar 2000 | WO |
WO-0027292 | May 2000 | WO |
WO-0041881 | Jul 2000 | WO |
WO-0042934 | Jul 2000 | WO |
WO-0051511 | Sep 2000 | WO |
WO-0051683 | Sep 2000 | WO |
WO-0056237 | Sep 2000 | WO |
WO-0057495 | Sep 2000 | WO |
WO-0067648 | Nov 2000 | WO |
WO-0067656 | Nov 2000 | WO |
WO-0067659 | Nov 2000 | WO |
WO-0067830 | Nov 2000 | WO |
WO-0067832 | Nov 2000 | WO |
WO-0113357 | Feb 2001 | WO |
WO-0122897 | Apr 2001 | WO |
WO-0137925 | May 2001 | WO |
WO-0170114 | Sep 2001 | WO |
WO-0180723 | Nov 2001 | WO |
WO-0182814 | Nov 2001 | WO |
WO-0205868 | Jan 2002 | WO |
WO-02083196 | Oct 2002 | WO |
WO-02085192 | Oct 2002 | WO |
WO-03003930 | Jan 2003 | WO |
WO-03059437 | Jul 2003 | WO |
WO-03099382 | Dec 2003 | WO |
WO-2004023978 | Mar 2004 | WO |
WO-2004091255 | Oct 2004 | WO |
WO-2005009218 | Feb 2005 | WO |
WO-2006041847 | Apr 2006 | WO |
WO-2006041881 | Apr 2006 | WO |
WO-2006060053 | Jun 2006 | WO |
WO-2007124458 | Nov 2007 | WO |
WO-2007135875 | Nov 2007 | WO |
WO-2007146834 | Dec 2007 | WO |
WO-2008003058 | Jan 2008 | WO |
WO-2008036479 | Mar 2008 | WO |
WO-2008052186 | May 2008 | WO |
WO-2008061152 | May 2008 | WO |
WO-2008151001 | Dec 2008 | WO |
WO-2009149315 | Dec 2009 | WO |
WO-2010033940 | Mar 2010 | WO |
WO-2010067360 | Jun 2010 | WO |
WO-2011046880 | Apr 2011 | WO |
WO-2011053757 | May 2011 | WO |
WO-2011082279 | Jul 2011 | WO |
WO-2011088399 | Jul 2011 | WO |
WO-2011094367 | Aug 2011 | WO |
WO-2011139589 | Nov 2011 | WO |
WO-2012112165 | Aug 2012 | WO |
Entry |
---|
Bhatt, et al., A Controlled Trial of Renal Denervation for Resistant Hypertension, N. Engl. J. Med., 370:1393-1401 (2014). |
Bunch, Jared, et al., Mechanisms of Phrenic Nerve Injury During Radiofrequency Ablation at the Pulmonary Vein Orifice, Journal of Cardiovascular Electrophysiology, 16(12):1318-1325 (2005). |
Campese, et al., Renal afferent denervation prevents hypertension in rats with chronic renal failure, Hypertension, 25:878-882 (1995). |
Dibona, Renal nerves in compensatory renal response to contralateral renal denervation, Renal Physiology, 238 (1):F26-F30 (1980). |
International Search Report & Written Opinion dated Jul. 9, 2014 in Int'l PCT Patent Application Serial No. PCT/US2014/22804. |
International Search Report & Written Opinion dated Nov. 29, 2011 in International PCT Patent Appl No. PCT/US2011/025543. |
International Search Report dated Feb. 9, 2014 in Int'l PCT Patent Application Serial No. PCT/US2014/022796. |
Medtronic Press Release, Medtronic Announces U.S. Renal Denervation Pivotal Trial Fails to Meet Primary Efficacy Endpoint While Meeting Primary Safety Endpoint, Jan. 9, 2014. |
Oliveira, et a., Renal Denervation Normalizes Pressure and Baroreceptor Reflex in High Renin Hypertension in Conscious Rats, Hypertension 19:17-21 (1992). |
OnlineMathLearning.com, Volume Formula, “Volume of a Hollow Cylinder”, Oct. 24, 2008. |
Smithwick, R.H., Surgery in hypertension, Lancet, 2:65 (1948). |
Smithwick, R.H., Surgical treatment of hypertension, Am J Med 4:744-759 (1948). |
Wang, S., et al., Effects of Low Intensity Ultrasound on the Conduction Property of Neural Tissues, IEEE International Ultrasonics, Ferroelectrics, and Frequency Control, Joint 50th Anniversary Conference, 2004. |
International Search Report & Written Opinion dated Jul. 9, 2014 in related Int'l PCT Patent Application Serial No. PCT/US2014/22804. |
Extended EP Search Report dated Dec. 5, 2016 in EP Patent Application Serial No. 16183988.1. |
www.dictionary.com/browse/degrease, retrieved Jun. 7, 2016. |
Arruda, M.S., et al. “Development and validation of an ECG algorithm for identifying accessory pathway ablation site in Wolff-Parkinson-White syndrome.” J Cardiovasc Electrophysiol, 9:2-12 (1998). |
Avitall, B., et al. “The creation of linear continuous lesions in the atria with an expandable loop catheter.” J Am Coll Cardiol, 33,4:972-974 (1999). |
Bartlett, T.G., et al. “Current management of the Wolff-Parkinson-White syndrome.” J Card Surg. 8:503-515 (1993). |
Benito, F., et al. “Radio frequency catheter ablation of accessory pathways in infants,” Heart, 78:160-162 (1997). |
Blumenfeld, J.D., et al. “β-Adrenergic receptor blockade as a therapeutic approach for suppressing the renin-angiotensin-aldosterone system in norrnotensive and hypertensive subjects.” AJH, 12:451-459 (1999). |
Callans, D. J. “Narrowing of the superior vena cava—right atrium junction during radiofrequency catheter ablation for inappropriate sinus tachycardia: Analysis with intracardiac echocardiography.” JACC, 33:1667-1670 (1999). |
Cao, H., et al. “Flow effect on lesion formation in RF cardiac catheter ablation.” IEEE T Bio-Med Eng, 48:425-433 (2001). |
Chen, S.-A., et al. “Complications of diagnostic electrophysiologic studies and radiofrequency catheter ablation in patients with tachyarrhythmias: An eight-year survey of 3,966 consecutive procedures in a tertiary referral center.” Am J Cardiol, 77:41-46 (1996). |
Chen, Shih-Ann, M.D., “Initiation of Atrial Fibrillation by Ectopic Beats Originating From the Pulmonary Veins,” Circulation 100(18):1879-86, 1999. |
Chinitz, et al., “Mapping Reentry Around Atriotomy Scars Using Double Potentials,” Pacing and Clinical Electrophysiology, Cardiostim 96 Proceedings, Part II, vol. 19:1978-1983 (1996). |
Cioni, R., et al. “Renal artery stenting in patients with a solitary functioning kidney.” Cardiovasc Intervent Radiol, 24:372-377 (2001). |
Cosby, R.L., et al. “The role of the sympathetic nervous system and vasopressin in the pathogenesis of the abnormal sodium and water.” Nefrologia, V, 4:271-277 (1985). |
Cosio, Francisco G., “Atrial Flutter Mapping and Ablation II,” Pacing & Clin. Electrophysiol. 19(6):965-75, 1996. |
Cox, J.L. “The status of surgery for cardiac arrhythmias.” Circulation, 71 :413-417 (1985). |
Cox, J.L. et al. “Five-year experience with the Maze procedure for atrial fibrillation.” Ann Thorac Surg, 56:814-824 (1993). |
Cruickshank, J.M. “Beta-blockers continue to surprise us.” Eur Heart J, 21:354-364 (2000). |
Curtis, J.J., et al. “Surgical therapy for persistent hypertension after renal transplantation,” Transplantation, 31:125-128 (1981). |
Demazumder, D., et al. “Comparison of irrigated electrode designs for radiofrequency ablation of myocardium.” J Intery Card Electr, 5:391-400 (2001). |
DiBona, G.F. “Neural control of the kidney: Functionally specific renal sympathetic nerve fibers.” Am J Physiol Regulatory Integrative Comp Physiol, 279:R1517-R1524 (2000). |
DiBona, G.F. “Sympathetic nervous system and kidney in hypertension,” Nephrol and Hypertension, 11:197-200 (2002). |
DiBona, G.F., et al. “Neural control of renal function,” Physiol Rev, 77:75-197 (1997). |
DiBona, G.F., et al. “Renal hemodynamic effects of activation of specific renal sympathetic nerve fiber groups.” Am J Physiol Regul Integr Comp Physiol, 276:R539-R539 (1999). |
Diederich C.J. et al. “Transurethral Ultrasound Array for Prostate Thermal Therapy: Initial Studies”, IEEE Transactions on Ultrasonic, Ferroelectronics and Frequency Control IEEEE USA, vol. 43, No. 6 Nov. 1996, pp. 1011-1022. |
Doggrell, S.A., et al. “Rat models of hypertension, cardiac hypertrophy and failure.” Cardiovasc Res, 39:89-105 (1998). |
Dong Q., et al. “Diagnosis of renal vascular disease with MR angiography.” RadioGraphies, 19:1535-1554 (1999). |
Dubuc, M., et al. “Feasibility of cardiac cryoablation using a transvenous steerable electrode catheter,” J Intery Cardiac Electrophysiol, 2:285-292 (1998). |
Feld, Gregory K., “Radiofrequency Catheter Ablation for the Treatment of Human Type I Atrial Flutter,” Circulation, 86(3):1233-1240 (1992). |
Gallagher, John J., “Wolff-Parkinson-White Syndrome: Surgery to Radiofrequency Catheter Ablation,” 1997. |
Gilard, M., et al. “Angiographic anatomy of the coronary sinus and its tributaries.” PACE, 21:2280-2284 (1998). |
Gorisch, W., et al. “Heat-induced contraction of blood vessels.” Lasers Surg Med, 2:1-13 (1982). |
Haines, D.E. et al. “Tissue heating during radiofrequency catheter ablation; A thermodynamic model and observations in isolated perfused and superfused canine right ventricular free wall.” PACE, 12:962-976 (1989). |
Haissaguerre, et al., “Radiofrequency Catheter Ablation in Unusual Mechanisms of Atrial Fibrillation,” Journal of Cardiovascular Electrophysiology, 5(9):743-1751 (1994). |
Haissaguerre, et al., “Right and Left Atrial Radiofrequency Catheter Therapy of Paroxysmal Atrial Fibrillation,” Journal of Cardiovascular Electrophysiology, 7(12):1133-1144 (1996). |
Haissaguerre, Michel, “Electrophysiological End Point for Catheter Ablation of Atrial Fibrillation Initiated From Multiple Venous Foci,” Circulation, 101:1409-1417 (2000). |
Haissaguerre, Michel, M.D., “Predominant Origin of Atrial Panarrhythmic Triggers in the Pulmonary Veins: A Distinct Electrophysiologic Entity,” 1997. |
Haissaguerre, Michel, M.D., et al., “Spontaneous Initiation of Atrial Fibrillation by Ectopic Beats Originating in the Pulmonary Veins,” The New England Journal of Medicine, 339(10):659-666 (1998). |
Han, Y-M., et al. “Renal artery embolization with diluted hot contrast medium: An experimental study,” J Vasc Interv Radiol, 12:862-868 (2001). |
Hansen, J.M., et al. “The transplanted human kidney does not achieve functional reinnervation.” Clin Sci, 87, 1:13-20 (1994). |
Hatala, Robert, “Radiofrequency Catheter Ablation of Left Atrial Tachycardia Originating Within the Pulmonary Vein in a Patient with Dextrocardia,” Pacing and Clinical Electrophysiology, 19(6):999-1002 (1996). |
Hindricks, G. “The Multicentre European Radiofrequency Survey (MERFS): Complications of radiofrequency catheter ablation of arrhythmias.” Eur Heart J, 14:1644-1653 (1993). |
Ho, S.Y., et al. “Architecture of the pulmonary veins: Relevance to the radiofrequency ablation.” Heart 86:265-270 (2001). |
Hocini, et al., “Concealed Left Pulmonary Vein Potentials Unmasked by Left Atrial Stimulation,” Pacing and Clinical Electrophysiology, 23(11):1828-1831, part 2 (2000). |
Hocini, et al., “Multiple Sources initiating Atrial Fibrillation from a Single Pulmonary Vein Identified by a Circumferential Catheter,” Pacing and Clinical Electrophysiology, 23(11):1828-1831, Part 2 (2000). |
Hsieh, et al., “Double Multielectrode Mapping Catheters Facilitate Radiofrequency Catheter Ablation of Focal Atrial Fibrillation Originating from Pulmonary Veins,” Journal of Cardiovascular Electrophysiology, 10(2):136-144 (1999). |
Huang et al., “Renal denervation prevents and reverses hyperinsulinemia-induced hypertension in rats,” Hypertension 32, pp. 249-54 (1998). |
Huang, S.K.S., et al. “Radiofrequency catheter ablation of cardiac arrhythmias: Basic concepts and clinical applications.” 2nd ed. Armonk, NY: Futura Publishing Co. (2000). |
Igawa, et al., “The Anatomical Features of the Junction between the Left Atrium and the Pulmonary Veins: The Relevance with Atrial Arrhythmia”, Circulation, Journal of the American Heart Association, Abstracts from the 72nd Scientific Sessions, 100(18):I-285 (1999). |
Jackman, W.M., et al. “Treatment of supraventricular tachycardia due to atrioventricular nodal reentry by radiofrequency catheter ablation of slow-pathway conduction.” N England J Med, 327, 5:313-318 (Jul. 30, 1992). |
Jain, M.K., et al. “A three-dimensional finite element model of radiofrequency ablation with blood flow and its experimental validation.” Ann Biomed Eng, 28:1075-1084 (2000). |
Jais, Pierre, M.D., “A Focal Source of Atrial Fibrillation Treated by Discrete Radiofrequency Ablation,” Circulation, 95(3):572-576 (1996). |
Janssen, B.J.A., et al. “Renal nerves in hypertension.” Miner Electrolyte Metab, 15:74-82 (1989). |
Kapural, L., et al. “Radiofrequency ablation for chronic pain control.” Curr Pain Headache Rep, 5:517-525 (2001). |
Kay, et al., “Radiofrequency Ablation for Treatment of Primary Atrial Tachycardia,” Journal of the American College of Cardiology, 21(4):901-909 (1993). |
Koepke, J.P., et al. “The physiology teacher: Functions of the renal nerves.” The Physiologist, 28, 1:47-52 (1985). |
Kompanowska-Jezierska, et al. “Early effects of renal denervation in the anaesthetised rat: Natriuresis and increased cortical blood flow,” J Physiol, 531.2:527-534 (2001). |
Krimholtz et al., “New Equivalent Circuits for Elementary Piezoelectric Transducers,” Electronics Lettres, vol. 6, No. 13, pp. 398-399, Jun. 25, 1970. |
Kumagai, et al., “Treatment of Mixed Atrial Fibrillation and Typical Atrial Flutter by Hybrid Catheter Ablation,” Pacing and Clinical Electrophysiology, 23(11):1839-1842, Part 2 (2000). |
Labonte, S. “Numerical model for radio-frequency ablation of the endocardium and its experimental validation.” IEEE T Bio-med Eng, 41,2:108-115 (1994). |
Lee, S.-J., et al. “Ultrasonic energy in endoscopic surgery,” Yonsei Med J, 40:545-549 (1999). |
Leertouwer, T.c., et al. “In-vitro validation, with histology, of intravascular ultrasound in renal arteries.” J Hypertens, 17:271-277 (1999). |
Lesh, M.D., “An Anatomic Approach to Prevention of Atrial Fibrillation: Pulmonary Vein Isolation with Through-the-Balloon Ultrasound Ablation (TTB-US),” Thorac. Cardiovasc. Surg. 47 (1999) (Suppl.) 347-51. |
Lesh, Michael D., M.D., “Radiofrequency Catheter Ablation of Atrial Arrhythmias,” Circulation, 89(3):1074-1089 (1994). |
Liem, L. Bing, “In Vitro and In Vivo Results of Transcatheter Microwave Ablation Using Forward-Firing Tip Antenna Design,” Pacing and Clinical Electrophysiology, Cardiostim '96 Proceedings, 19(11), Part 2 pp. 2004-2008 (1996). |
Lin, Wei-Shiang, M.D., “Pulmonary Vein Morphology in Patients with Paroxysmal Atrial Fibrillation Initiated by Ectopic Beats Originating From the Pulmonary Veins,” Circulation 101(11):1274-81, 2000. |
Lowe, J.E. “Surgical treatment of the Wolff-Parkinson-White syndrome and other supraventricular tachyarrhythmias.” J Card Surg, 1 :117-134 (1986). |
Lundin, S. et al. “Renal sympathetic activity in spontaneously hypertensive rats and normotensive controls, as studied by three different methods.” Acta Physiol Scan, 120,2:265-272 (1984). |
Lustgarten, D.L., et al. “Cryothermal ablation: Mechanism of tissue injury and current experience in the treatment of tachyarrhythmias,” Progr Cardiovasc Dis, 41:481-498 (1999). |
Mallavarapu,Christopher, “Radiofrequency Catheter Ablation of Atrial Tachycardia with Unusual Left Atrial Sites of Origin,” Pacing and Clinical Electrophysiology, vol. 19(6), pp. 988-992 (1996). |
McRury, I.D., et al. “Nonuniform heating during radiofrequency catheter ablation with long electrodes.” Circulation, 96:4057-4064 (1997). |
Mehdirad, A., et al. “Temperature controlled RF ablation in canine ventricle and coronary sinus using 7 Fr or 5 Fr ablation electrodes.” PACE, 21:310-321 (1998). |
Miller, B.F., and Keane, C.B. “Miller-Keane Encyclopedia & Dictionary of Medicine, Nursing, & Allied Health.” Philadelphia: Saunders (1997) (“ablation”). |
Misaki, T., et al. “Surgical treatment of patients with Wolff-ParkinsonWhite syndrome and associated Ebstein's anomaly.” J Thorae Cardiovase Surg, 110: 1702-1707 (1995). |
Moak, J.P., et al. “Case report: Pulmonary vein stenosis following RF ablation of paroxysmal atrial fibrillation: Successful treatment with balloon dilation.” J Intery Card Electrophys, 4:621-631 (2000). |
Montenero, Sandro, Annibale, “Electrograms for Identification of the Atrial Ablation Site During Catheter Ablation of Accessory Pathways,” Pacing and Clinical Electrophysiology, vol. 19(6), pp. 905-912 (1996). |
Morrissey, D.M., “Sympathectomy in the treatment of hypertension.” Lancet, CCLXIV:403-408 (1953). |
Moubarak, Jean B., “Pulmonary Veins-Left Atrial Junction: Anatomic and Histological Study,” Pacing & Clin. Electrophys. 23(11 pt. 2):1836-8, 2000. |
Nakagawa, A., et al. “Selective ablation of porcine and rabbit liver tissue using radiofrequency: Preclinical study.” Eur Surg Res, 31:371-379 (1999). |
Nakagawa, H., et al. “Comparison of in vivo tissue temperature profile and lesion geometry for radiofrequency ablation with a saline-irrigated electrode versus temperature control in a eanine thigh muscle preparation.” Circulation, 91 :2264-2273 (1995). |
Nakagawa, H., et al. “Inverse relationship between electrode size and lesion size during radiofrequency ablation with active electrode cooling.” Circulation, 98:458-465 (1998). |
Neutel, J. M. “Hypertension and its management: A problem in need of new treatment strategies.” JRAAS, I:S 1 O-S 13 (2000). |
Nozawa, T., et al. “Effects of long-term renal sympathetic denervation on heart failure after myocardial infarction in rats.” Heart Vessels, 16:51-56 (2002). |
O'Connor, B.K., et al. “Radiofrequency ablation of a posteroseptal accessory pathway via the middle cardiac vein in a six-year-old child.” PACE, 20:2504-2507 (1997). |
Oliveira et al., “Renal Denervation Normalized Pressure and Baroreceptor Reflex in High Renin Hypertension in Conscious Rats,” Hypertension Suppl. II vol. 19 No. 2 pp. 17-21 (1992). |
Oral, H., et al. “Pulmonary vein isolation for paroxysmal and persistent atrial fibrillation.” Circulation, 105: 1077-1081 (2002). |
Page, I., et al. “The effect of renal denervation in the level of arterial blood pressure and renal function in essential hypertension.” J Clin Invest, XIV:27-30 (1935). |
Panescu, D., et al. “Radiofrequency multielectrode catheter ablation in the atrium.” Phys Med Biol, 44:899-915 (1999). |
Pavin, D., et al. “Permanent left atrial tachycardia: Radiofrequency catheter ablation through the coronary sinus.” J Cardiovasc Electrophysiol, 12:395-398 (2002). |
Peet, M., “Hypertension and its surgical treatment by bilateral supradiaphragmatic splanchnicectomy,” Am. J. Surgery, pp. 48-68 (1948).g. |
Petersen, H. H., et al. “Lesion dimensions during temperature controlled radiofrequency catheter ablation of left ventricular porcine myocardium: Impact of ablation site, electrode size, and convective cooling.” Circulation, 99:319-325 (1999). |
Pohl, M.A. “Renovascular hypertension and ischemic nephropathy” A chapter in a book edited by Sehrier, R.W. “Atlas of diseases of the kidney: Hypertension and the kidney.” Blackwell Science (1999). |
Prager, Nelson, A., “Long Term Effectiveness of Surgical Treatment of Ectopic Atrial Tachycardia,” Journal of the American College of Cardiology, vol. 22(1):85-92 (1993). |
Pugsley, M.K., et al. “The vascular system an overview of structure and function.” J Pharmacol Toxical Methods, 44:333-340 (2000). |
Rappaport et al. “Wide-Aperture Microwave Catheter-Based Cardiac Ablation”, Proceedings of the First Joint BMES/EMBS Conference, Oct. 13-16, 1999, p. 314. |
Reuter, David, M.D., et al., “Future Directions of Electrotherapy for Atrial Fibrillation,” Journal of Cardiovascular Electrophysiology, 9(8):S202-S210 (1998). |
Robbins, Ivan, M.D., “Pulmonary Vein Stenosis After Catheter Ablation of Atrial Fibrillation,” Circulation, 98:1769-1775 (1998). |
Sanderson, J.E., et al. “Effect of B-blockage on baroreceptor and autonomic function in heart failure.” Clin Sei, 69:137-146 (1999). |
Schauerte, P., et al. “Catheter ablation of cardiac autonomic nerves for prevention of vagal atrial fibrillation,” Circulation, 102:2774-2780 (2000). |
Scheinman, M. M., et al. “The 1998 NASPE prospective catheter ablation registry.” PACE, 23:1020-1028 (2000). |
Scheinman, Melvin M., “NASPE Survey on Catheter Ablation,” 1995. |
Smithwick et al., “Splanchnicetomy for Essential Hypertension,” J. Am. Med. Assn. 152:16, pp. 1501-04 (1953). |
Solis-Herruzo et al., “Effects Lumbar Sympathetic Block on Kidney Function in Cirrhotic Patients with Hepatorneal Syndrome,” J. Hepatol. 5, pp. 167-173 (1987). |
Stella, A., et al. “Effects of reversible renal denervation on hemodynamic and excretory functions of the ipsilateral and contralateral kidney in the cat,” J Hypertension, 4:181-188 (1986). |
Stellbrink, C., et al. “Transcoronary venous radiofrequency catheter ablation of ventricular tachycardia.” J Cardiovasc Electropysiol 8:916-921 (1997). |
Swain, et al., An endoscopically deliverable tissue-transfixing device for securing biosensors in the gastrointestinal tract, Gastrointestinal Endoscopy. 1994, 40:AB35. |
Swartz, John F., “A Catheter-based Curative Approach to Atrial Fibrillation in Humans,” Circulation, Abstracts from the 67th Scientific Sessions, Clinical Cardiology: Radio Frequency Ablation of Atrial Arrhythmias, 90(4), part 2, I-335 (1994). |
Swartz, John F., M.D., “Radiofrequency Endocardial Catheter Ablation of Accessory Atrioventricular Pathway Atrial Insertion Sites,” Circulation, 87:487-499 (1993). |
Takahashi, H., et al. “Retardation of the development of hypertension in DOCA-salt rats by renal denervation.” Jpn Circ J, 48:567-574 (1984). |
Tanaka et al., “A new radiofrequency thermal balloon catheter for pulmonary vein isolation,” Journal of the American College of Cardiology 38(7): 2079-86, Dec. 2001. |
Tracy, Cynthia M., “Radiofrequency Catheter Ablation of Ectopic Atrial Tachycardia Using Paced Activation Sequence Mapping,” J. of the Amer. College of Cardiol. 21(4):910-7, 1993. |
Tungjitkusolmun, S. “Ablation.” A chapter in a book edited by Webster, J. G., “Minimally invasive medical technology.” Bristol UK: IOP Publishing, 219 (2001). |
Uchida, F., et al. “Effect of radio frequency catheter ablation on parasympathetic denervation: A comparison of three different ablation sites,” PACE, 21:2517-2521 (1998). |
Uflacker, R., “Atlas of vascular anatomy: An angiographic approach.” Baltimore: Williams & Wilkins, 424 (1997). |
Valente, J. F. “Laparoscopic renal denervation for intractable ADPKD-related pain,” Nephrol Dial Transplant, 16:160 (2001). |
Van Hare, G. F., et al. “Percutaneous radiofrequency catheter ablation for supraventricular arrhythmias in children.” JACC, 17:1613-1620 (1991). |
Van Hare, George F., “Radiofrequency Catheter Ablation of Supraventricular Arrhythmias in Patients With Congenital Heart Disease: Results and Technical Considerations,” J. of the Amer. College of Cardiol. 22(3):883-90, 1993. |
Volkmer, Marius, M.D., “Focal Atrial Tachycardia from Deep Inside the Pulmonary Veins,” PACE vol. 20:533, p. 1183 (1997). |
Vujaskovie, Z., et al. “Effects of intraoperative hyperthermia on canine seiatie nerve: Histopathology and morphometric studies.” Int JHyperthermia, 10,6:845-855 (1994). |
Walsh, Edward P., M.D., “Transcatheter Ablation of Ectopic Atrial Tachycardia in Young Patients Using Radiofrequency Current,” Circulation, 86(4):1138-1146 (1992). |
Weinstock, M., et al. “Renal denervation prevents sodium retention and hypertension in salt-sensitive rabbits with genetic baroreflex impairment,” Clinical Science, 90:287-293 (1996). |
Weir, M. R., et al. “The renin-angiotensin-aldosterone system: A specific target for hypertension management.” Am J Hypertens,12:205S-213S (1999). |
Yamamoto, T., et al. “Blood velocity profiles in the human renal artery by Doppler ultrasound and their relationship to atherosclerosis.” Arterisocl Throm Vas, 16: 172-177 (1996). |
Zhang et al., “The development of a RF electrical pole catheter for heart ablation,” China Academic Journal Electronic Publishing House 23(5): 279-80, Sep. 1999 (With English Abstract). |
Zipes, Douglas P., M.D., “Catheter Ablation of Arrhythmias,” 1994. |
Number | Date | Country | |
---|---|---|---|
20140277033 A1 | Sep 2014 | US |
Number | Date | Country | |
---|---|---|---|
61784790 | Mar 2013 | US |